The First Wave of AI-Designed Drugs Hits Human Trials: A 2026 Status Report on Insilico, Isomorphic, and Recursion
As of May 2026, more than 75 AI-discovered drugs are in human trials. Inside the Insilico IPF Phase 2 program, Isomorphic Labs partnerships with Novartis and Lilly, Recursion’s Phase 2…
